MA46888A - Inhibiteurs de gsk-3 - Google Patents
Inhibiteurs de gsk-3Info
- Publication number
- MA46888A MA46888A MA046888A MA46888A MA46888A MA 46888 A MA46888 A MA 46888A MA 046888 A MA046888 A MA 046888A MA 46888 A MA46888 A MA 46888A MA 46888 A MA46888 A MA 46888A
- Authority
- MA
- Morocco
- Prior art keywords
- gsk
- inhibitors
- Prior art date
Links
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426630P | 2016-11-28 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46888A true MA46888A (fr) | 2021-06-02 |
Family
ID=60655129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046888A MA46888A (fr) | 2016-11-28 | 2017-11-27 | Inhibiteurs de gsk-3 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10774086B2 (fr) |
| EP (1) | EP3544980B1 (fr) |
| JP (1) | JP6977038B2 (fr) |
| KR (1) | KR102611539B1 (fr) |
| CN (1) | CN110225912B (fr) |
| ES (1) | ES2896938T3 (fr) |
| MA (1) | MA46888A (fr) |
| WO (1) | WO2018098411A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN111620881B (zh) * | 2020-07-08 | 2023-03-31 | 浙江合聚生物医药有限公司 | 拉罗替尼衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29823A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones |
| KR20070077468A (ko) * | 2006-01-23 | 2007-07-26 | 크리스탈지노믹스(주) | 단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물 |
| MX2009001913A (es) * | 2006-08-23 | 2009-03-06 | Pfizer Prod Inc | Compuestos de pirimidona como inhibidores de gsk-3. |
| KR20100049073A (ko) * | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
| DK2694510T3 (en) * | 2011-04-07 | 2016-01-18 | Bayer Ip Gmbh | IMIDAZOPYRIDAZINER AS AKT kinase inhibitors |
| EP2768833A4 (fr) * | 2011-10-20 | 2015-04-15 | Sirtris Pharmaceuticals Inc | Aza-hétérocycles bicycliques substitués et analogues en tant que modulateurs des sirtuines |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
-
2017
- 2017-11-27 WO PCT/US2017/063230 patent/WO2018098411A1/fr not_active Ceased
- 2017-11-27 MA MA046888A patent/MA46888A/fr unknown
- 2017-11-27 US US16/463,451 patent/US10774086B2/en active Active
- 2017-11-27 CN CN201780084338.1A patent/CN110225912B/zh active Active
- 2017-11-27 EP EP17812187.7A patent/EP3544980B1/fr active Active
- 2017-11-27 ES ES17812187T patent/ES2896938T3/es active Active
- 2017-11-27 JP JP2019528536A patent/JP6977038B2/ja active Active
- 2017-11-27 KR KR1020197018281A patent/KR102611539B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2896938T3 (es) | 2022-02-28 |
| JP6977038B2 (ja) | 2021-12-08 |
| CN110225912A (zh) | 2019-09-10 |
| EP3544980B1 (fr) | 2021-10-13 |
| KR20190085112A (ko) | 2019-07-17 |
| EP3544980A1 (fr) | 2019-10-02 |
| US10774086B2 (en) | 2020-09-15 |
| JP2019535790A (ja) | 2019-12-12 |
| CN110225912B (zh) | 2022-10-21 |
| KR102611539B1 (ko) | 2023-12-06 |
| US20190276463A1 (en) | 2019-09-12 |
| WO2018098411A1 (fr) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| IL269196A (en) | Novel inhibitors | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| EP3347008A4 (fr) | Inhibiteurs de bêta-lactamases | |
| MA53944A (fr) | Inhibiteurs de la glycosidase | |
| CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| EP3313828A4 (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| EP3541820A4 (fr) | Inhibiteurs de magl | |
| MA46857A (fr) | Inhibiteurs de magl | |
| EP3541822A4 (fr) | Inhibiteurs de magl | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA46889A (fr) | Inhibiteurs de gsk-3 | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| EP3600301A4 (fr) | Inhibiteurs de kdm4 | |
| DK3481826T3 (da) | Tyrosinkinaseinhibitorer | |
| EP3519429A4 (fr) | Inhibiteurs bactériens | |
| MA44607A (fr) | Inhibiteurs de kinase |